Denosumab Better for Breast Cancer With Bone Metastases

Share this article:
Denosumab Better for Breast Cancer With Bone Metastases
Denosumab Better for Breast Cancer With Bone Metastases

(HealthDay News) -- In women with advanced breast cancer and bone metastases, denosumab is better than zoledronic acid in preventing skeletal complications and improving health-related quality of life, according to a study published online Aug. 14 in Clinical Cancer Research.

Building on their previous phase III study that showed denosumab to be superior to zoledronic acid in preventing skeletal complications in patients with breast cancer and bone metastases, Miguel Martin, M.D., Ph.D., from the Hospital General Universitario Gregorio Maranon in Madrid, and colleagues further analyzed results of the study, in which 2,046 women had been randomized to receive subcutaneous denosumab and intravenous placebo or intravenous zoledronic acid and subcutaneous placebo.

The researchers found that denosumab was superior to zoledronic acid, with significantly fewer patients having a skeletal-related event (31 versus 36 percent). The incidence of first radiation to bone was also lower (12 versus 16 percent). Compared with zoledronic acid, denosumab increased the time to first radiation to bone by 26 percent and to first skeletal-related event or hypercalcemia of malignancy by 18 percent. In addition, 10 percent more patients taking denosumab had a clinically meaningful improvement in health-related quality of life, which was independent of baseline pain levels.

"Denosumab offers an efficacious and well-tolerated treatment option for preventing skeletal complications in patients with breast cancer and bone metastases," Martin and colleagues conclude.

The study was funded by Amgen; several authors disclosed financial ties to pharmaceutical companies, including Amgen.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Interval tumors found in six percent of colorectal cancer cases

Interval tumors found in six percent of colorectal ...

Interval cancers more likely to be earlier stage, proximal, have lower risk of death

Reliance on Windows XP may threaten data security

Reliance on Windows XP may threaten data security

Continued security of patient data is needed following Microsoft's termination of XP support.

Perioperative chemotherapy increases bladder cancer survival

Perioperative chemotherapy increases bladder cancer survival

Study shows low utilization of bladder cancer perioperative chemotherapy is associated with a survival benefit in the general population.